NASDAQ:AVXL - Anavex Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.67
  • Forecasted Upside: 250.24 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.04
▲ +0.74 (7.18%)

This chart shows the closing price for AVXL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anavex Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVXL

Analyst Price Target is $38.67
▲ +250.24% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Anavex Life Sciences in the last 3 months. The average price target is $38.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 250.24% upside from the last price of $11.04.

This chart shows the closing price for AVXL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Anavex Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/23/2022Berenberg BankInitiated CoverageBuy$40.00Low
3/16/2022HC WainwrightReiterated RatingBuy$42.00High
2/2/2022HC WainwrightBoost Price TargetBuy$39.00 ➝ $42.00High
11/25/2021BTIG ResearchReiterated RatingBuy$34.00Low
11/19/2021BTIG ResearchReiterated RatingBuy$35.00High
10/14/2021HC WainwrightReiterated RatingBuy$39.00Low
9/23/2021BTIG ResearchInitiated CoverageBuy$35.00High
6/28/2021Cantor FitzgeraldBoost Price TargetOverweight$31.00 ➝ $40.00High
6/28/2021HC WainwrightReiterated RatingBuy$25.00 ➝ $39.00Low
6/21/2021Dawson JamesBoost Price TargetBuy$19.00 ➝ $35.00Low
6/15/2021HC WainwrightBoost Price TargetBuy$17.00 ➝ $25.00High
6/14/2021JonestradingReiterated RatingBuy$35.00High
3/1/2021Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $25.00N/A
2/23/2021Cantor FitzgeraldBoost Price TargetOverweight$10.00 ➝ $25.00High
2/17/2021LADENBURG THALM/SH SHReiterated RatingBuy$20.00Low
12/16/2020HC WainwrightBoost Price TargetPositive ➝ Buy$14.00 ➝ $17.00N/A
10/21/2020HC WainwrightBoost Price TargetBuy$12.00 ➝ $14.00Low
9/28/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.00High
8/11/2020HC WainwrightReiterated RatingBuyLow
6/16/2020HC WainwrightReiterated RatingBuy$12.00High
6/8/2020Dawson JamesReiterated RatingBuy$16.00Medium
6/8/2020Janney Montgomery ScottReiterated RatingBuy$10.00Medium
6/8/2020Cantor FitzgeraldReiterated RatingBuy$8.00Medium
6/5/2020HC WainwrightReiterated RatingBuy$12.00High
5/22/2020HC WainwrightReiterated RatingBuy$12.00Low
5/8/2020HC WainwrightReiterated RatingBuy$12.00High
4/1/2020HC WainwrightReiterated RatingBuy$12.00High
3/16/2020HC WainwrightInitiated CoverageBuy$12.00Medium
2/26/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
7/24/2019Dawson JamesInitiated CoverageBuy$16.00Low
6/18/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$10.00High
5/23/2019Roth CapitalReiterated RatingBuyMedium
2/8/2019Roth CapitalSet Price TargetBuy$10.00High
1/28/2019Roth CapitalInitiated CoverageBuy$10.00Low
12/13/2018Maxim GroupSet Price TargetBuy$7.00High
10/31/2018HC WainwrightSet Price TargetBuy$10.00Low
10/26/2018Maxim GroupSet Price TargetBuy$7.00Medium
10/22/2018HC WainwrightReiterated RatingBuy$10.00High
10/19/2018Maxim GroupSet Price TargetBuy$7.00High
8/28/2018Maxim GroupSet Price TargetBuy$7.00Low
8/28/2018HC WainwrightSet Price TargetBuy$10.00Medium
8/10/2018HC WainwrightSet Price TargetBuy$10.00High
8/9/2018Maxim GroupReiterated RatingBuy$7.00Low
7/25/2018HC WainwrightSet Price TargetBuy$10.00High
7/10/2018HC WainwrightSet Price TargetBuy$10.00Low
7/9/2018Maxim GroupInitiated CoverageBuy$7.00Low
7/3/2018Maxim GroupInitiated CoverageBuy$7.00Low
7/3/2018HC WainwrightSet Price TargetBuy$10.00High
5/31/2018Maxim GroupReiterated RatingBuy$5.00 ➝ $7.00Low
5/30/2018HC WainwrightInitiated CoverageBuy$10.00High
5/16/2018Noble FinancialSet Price TargetBuy$7.00High
5/16/2018Maxim GroupInitiated CoverageBuy$5.00 ➝ $7.00High
3/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$6.00High
2/21/2018Noble FinancialReiterated RatingBuyLow
2/14/2018Maxim GroupSet Price TargetBuy$5.00Low
2/8/2018Maxim GroupSet Price TargetBuy ➝ Buy$14.00 ➝ $5.00Low
12/12/2017Noble FinancialReiterated RatingBuyMedium
12/11/2017Maxim GroupSet Price TargetBuy$14.00High
10/30/2017Maxim GroupSet Price TargetBuy$15.00N/A
10/12/2017Maxim GroupSet Price TargetBuy$15.00N/A
9/29/2017Noble FinancialReiterated RatingBuy ➝ Buy$15.00Low
8/9/2017Noble FinancialReiterated RatingBuyHigh
8/7/2017Maxim GroupSet Price TargetBuy$15.00Low
7/20/2017Maxim GroupReiterated RatingBuy$15.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/5/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Anavex Life Sciences logo
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Read More

Today's Range

Now: $11.04
Low: $10.10
High: $11.05

50 Day Range

MA: $8.96
Low: $7.31
High: $11.04

52 Week Range

Now: $11.04
Low: $7.13
High: $28.26

Volume

1,109,877 shs

Average Volume

1,058,391 shs

Market Capitalization

$854.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Anavex Life Sciences?

The following Wall Street research analysts have issued research reports on Anavex Life Sciences in the last twelve months: Berenberg Bank, BTIG Research, HC Wainwright, and StockNews.com.
View the latest analyst ratings for AVXL.

What is the current price target for Anavex Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Anavex Life Sciences in the last year. Their average twelve-month price target is $38.67, suggesting a possible upside of 250.2%.
View the latest price targets for AVXL.

What is the current consensus analyst rating for Anavex Life Sciences?

Anavex Life Sciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVXL will outperform the market and that investors should add to their positions of Anavex Life Sciences.
View the latest ratings for AVXL.

How do I contact Anavex Life Sciences' investor relations team?

Anavex Life Sciences' physical mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is (844) 689-3939 and its investor relations email address is [email protected] The official website for Anavex Life Sciences is www.anavex.com. Learn More about contacing Anavex Life Sciences investor relations.